Healthcare of Ontario Pension Plan Trust Fund boosted its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 383.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 67,517 shares of the company's stock after acquiring an additional 53,540 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund's holdings in Zoetis were worth $13,191,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Asset Dedication LLC grew its holdings in shares of Zoetis by 4.8% during the second quarter. Asset Dedication LLC now owns 1,174 shares of the company's stock worth $204,000 after buying an additional 54 shares in the last quarter. Forza Wealth Management LLC boosted its position in Zoetis by 1.8% during the 2nd quarter. Forza Wealth Management LLC now owns 3,313 shares of the company's stock worth $574,000 after acquiring an additional 58 shares during the last quarter. Cherry Creek Investment Advisors Inc. grew its stake in shares of Zoetis by 2.0% during the 3rd quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company's stock worth $590,000 after acquiring an additional 58 shares in the last quarter. L. Roy Papp & Associates LLP raised its holdings in shares of Zoetis by 2.8% in the second quarter. L. Roy Papp & Associates LLP now owns 2,221 shares of the company's stock valued at $385,000 after purchasing an additional 60 shares during the last quarter. Finally, Grove Bank & Trust lifted its position in shares of Zoetis by 0.5% in the third quarter. Grove Bank & Trust now owns 11,763 shares of the company's stock worth $2,298,000 after purchasing an additional 61 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.
Zoetis Stock Performance
Shares of NYSE:ZTS traded down $1.49 on Friday, hitting $175.25. The company had a trading volume of 1,543,442 shares, compared to its average volume of 2,545,743. The stock has a market cap of $79.07 billion, a price-to-earnings ratio of 32.94, a P/E/G ratio of 2.71 and a beta of 0.90. The stock has a 50 day moving average price of $183.83 and a 200 day moving average price of $180.84. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26.
Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating analysts' consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the prior year, the business earned $1.36 EPS. Zoetis's quarterly revenue was up 11.6% on a year-over-year basis. Analysts expect that Zoetis Inc. will post 5.9 EPS for the current year.
Zoetis Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be paid a $0.432 dividend. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 annualized dividend and a yield of 0.99%. Zoetis's dividend payout ratio (DPR) is presently 32.52%.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on the stock. Piper Sandler lifted their price target on shares of Zoetis from $195.00 to $210.00 and gave the company an "overweight" rating in a research note on Wednesday, August 14th. JPMorgan Chase & Co. upped their target price on Zoetis from $225.00 to $230.00 and gave the stock an "overweight" rating in a report on Friday, October 11th. BTIG Research increased their price target on Zoetis from $220.00 to $225.00 and gave the company a "buy" rating in a research report on Monday, August 12th. Argus raised Zoetis to a "strong-buy" rating in a research report on Friday, August 9th. Finally, Stifel Nicolaus increased their price objective on Zoetis from $200.00 to $210.00 and gave the company a "buy" rating in a report on Wednesday, September 18th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $221.44.
Check Out Our Latest Research Report on Zoetis
Zoetis Company Profile
(
Free Report)
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Read More
Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.